No registrations found.
ID
Source
Brief title
Health condition
malignancy
sarcoma
gastrointestinal stromal tumour
Sponsors and support
Erasmus MC - Daniel den Hoed Cancer Center
Groene Hilledijk 301
3075 EA Rotterdam
Intervention
Outcome measures
Primary outcome
- To investigate the influence of rosuvastatin on the plasma pharmacokinetics of imatinib (and its metabolite CGP74588) in GIST cancer patients.
Secondary outcome
- To correlate genetic polymorphisms in enzymes and drug transporting pumps [40,41] with imatinib pharmacokinetics and adverse effects in GIST cancer patients (according to METC protocol 02-1002).
- To study possible side-effects due to the combination treatment of imatinib and rosuvastatin.
Background summary
Since the bioavailability of imatinib is usually almost complete, it might be possible that OATP 1A2 mediated transport of imatinib is extremely efficient, so that efflux transporters (i.e. P-glycoprotein and BCRP) cannot lower the bioavailability of this compound.
A possibly competitive inhibition between imatinib and rosuvastatin as substrates for the same solute carriers (i.e. OATP 1A2 and ABCG2) may result in drug-drug interactions and altered pharmacokinetics of imatinib.
To elucidate the clinical importance of this hypothesis we study the effects of concomitant administration of rosuvastatin and imatinib on the pharmacokinetics of imatinib. In this pharmacokinetic study, we would like to expose GIST patients at steady-state concentrations of imatinib to rosuvastatin. We will compare the (plasma) pharmacokinetics of imatinib and its metabolite CGP74588 at steady state with the pharmacokinetics after exposure to rosuvastatin.
We feel this study is clinically relevant, as rosuvastatin is a widely used HMG Co-A reductase inhibitor among cancer patients in the Netherlands. Therefore possible ‘chronic’ drug-drug interactions between imatinib and rosuvastatin may be of important abundance in daily clinical practice. As our patients are exposed only for a short period of time (16 days) and monitored closely, we expect the possible negative effects of a decreased exposure to imatinib will be negligible. This is especially true, as imatinib will have its clinical effects as a result of its usage during months or even years, in contrast to chemotherapy.
Study objective
A possibly competitive inhibition between imatinib and rosuvastatin as substrates for the same solute carriers (i.e. OATP 1A2 and ABCG2) may result in drug-drug interactions and altered pharmacokinetics of imatinib.
Study design
Study plan:
Day -28 /Day -1:
Informed consent, check of inclusion/exclusion criteria (see section 4), and registration (see section 9: registration procedure). Daily use of imatinib
· Day 1: Hospitalization of the patient; and Start of PK sampling (see section 13: tables).
· Day 2: Use of rosuvastatin at 10 AM after the use of breakfast, 30 minutes later
followed by the use of imatinib.
· Day 3-15: Extramural use of rosuvastatin, 20 mg daily, and imatinib 400 or 800
mg daily.
· Day 16: Second period of PK-sampling.
· Day 17: Stop use of rosuvastatin.
Intervention
This pharmacokinetic study, we would like to expose GIST patients at steady-state concentrations of imatinib to rosuvastatin. We will compare the (plasma) pharmacokinetics of imatinib and its metabolite CGP74588 at steady state with the pharmacokinetics after exposure to rosuvastatin.
2 blood sample collections
2 PK daycurves
Department of Medical Oncology <br> Room G4-80
Karel Eechoute
Groene Hilledijk 301
Rotterdam 3075 EA
The Netherlands
+31 10 7041338, buzzer 773
k.eechoute@erasmusmc.nl
Department of Medical Oncology <br> Room G4-80
Karel Eechoute
Groene Hilledijk 301
Rotterdam 3075 EA
The Netherlands
+31 10 7041338, buzzer 773
k.eechoute@erasmusmc.nl
Inclusion criteria
1. Histological or cytological confirmed diagnosis of any form of irresectable and/or metastatic GIST, which is already treated with imatinib for a consecutive period of at least 4 weeks;
2. Age ³ 18 years;
3. WHO performance £ 1 (see appendix B);
4. Adequate hematological functions (ANC > 1.5 x 109/L, platelets > 100 x 1012/L);
5. Adequate renal and hepatic functions (serum creatinin < 1.25xULN, bilirubin < 1.25xULN, ALAT and ASAT < 2.5xULN, in case of liver metastasis < 5 ULN; alkaline phosphatase < 5xULN);
6. Written informed consent;
7. Complete initial work-up within four weeks prior to therapy with the combination of imatinib and rosuvastatin.
Exclusion criteria
1. Pregnant or lactating patients; patients with reproductive potential must use a reliable method of contraception (excluding oral contraceptives), if required;
2. Serious illness or medical unstable condition requiring treatment, symptomatic CNS-metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;
3. Use of imatinib therapy less than 4 consecutive weeks;
4. Major surgery within 2 weeks before start of the protocol (to be evaluated by an MD);
5. (Chronic) use of CYP3A and/or P-glycoprotein inhibiting and inducing medication (in particular cyclosporine, which may result in a severe rise of rosuvastatin plasmaconcentration) dietary supplements, or other inhibiting compounds (see Appendix D);
6. Unwillingness to change medication, or no adequate alternatives available, when drugs are taken that are known to interact with CYP3A and/or ABCB1 and/or ABCG2;
7. Asian patients;
8. Use of statins 4 weeks prior to study entry;
9. Patients suffering from myopathy (CK > 10 x ULN associated with muscle symptoms).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1443 |
| NTR-old | NTR1504 |
| Other | EudraCTnumber 2008-002659-26 : 08-256 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |